Jiangsu Hengrui Medicine Co Ltd

SHG:600276 China Drug Manufacturers - Specialty & Generic
Market Cap
$47.91 Billion
CN¥351.55 Billion CNY
Market Cap Rank
#721 Global
#18 in China
Share Price
CN¥55.11
Change (1 day)
-0.34%
52-Week Range
CN¥44.35 - CN¥72.47
All Time High
CN¥193.72
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more

Jiangsu Hengrui Medicine Co Ltd (600276) - Net Assets

Latest net assets as of September 2025: CN¥60.03 Billion CNY

Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has net assets worth CN¥60.03 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥68.33 Billion) and total liabilities (CN¥8.30 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥60.03 Billion
% of Total Assets 87.86%
Annual Growth Rate 25.71%
5-Year Change 49.71%
10-Year Change 344.98%
Growth Volatility 56.16

Jiangsu Hengrui Medicine Co Ltd - Net Assets Trend (1997–2024)

This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jiangsu Hengrui Medicine Co Ltd (1997–2024)

The table below shows the annual net assets of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024.

Year Net Assets Change
2024-12-31 CN¥46.09 Billion +12.32%
2023-12-31 CN¥41.03 Billion +6.82%
2022-12-31 CN¥38.41 Billion +7.99%
2021-12-31 CN¥35.57 Billion +15.54%
2020-12-31 CN¥30.79 Billion +23.46%
2019-12-31 CN¥24.94 Billion +25.96%
2018-12-31 CN¥19.80 Billion +24.18%
2017-12-31 CN¥15.94 Billion +23.84%
2016-12-31 CN¥12.87 Billion +24.30%
2015-12-31 CN¥10.36 Billion +24.94%
2014-12-31 CN¥8.29 Billion +24.55%
2013-12-31 CN¥6.66 Billion +22.29%
2012-12-31 CN¥5.44 Billion +24.30%
2011-12-31 CN¥4.38 Billion +26.01%
2010-12-31 CN¥3.47 Billion +30.39%
2009-12-31 CN¥2.67 Billion +31.64%
2008-12-31 CN¥2.02 Billion +23.96%
2007-12-31 CN¥1.63 Billion +29.94%
2006-12-31 CN¥1.26 Billion +13.43%
2005-12-31 CN¥1.11 Billion +11.03%
2004-12-31 CN¥998.05 Million +10.48%
2003-12-31 CN¥903.35 Million +11.53%
2002-12-31 CN¥809.97 Million +6.86%
2001-12-31 CN¥757.99 Million +12.70%
2000-12-31 CN¥672.57 Million +313.79%
1999-12-31 CN¥162.54 Million +14.84%
1998-12-31 CN¥141.53 Million +48.13%
1997-12-31 CN¥95.54 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Hengrui Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 138979.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥33.87 Billion 74.40%
Common Stock CN¥6.38 Billion 14.01%
Other Comprehensive Income CN¥16.97 Million 0.04%
Other Components CN¥5.26 Billion 11.55%
Total Equity CN¥45.52 Billion 100.00%

Jiangsu Hengrui Medicine Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their market capitalization.

Company Market Cap
Chugai Pharmaceutical Co. Ltd
PINK:CHGCF
 		$28.30 Billion
HUATEI SECS.CO GDR S/10
F:206G
 		$28.31 Billion
Tata Consultancy Services Limited
NSE:TCS
 		$28.40 Billion
Workday Inc
NASDAQ:WDAY
 		$28.57 Billion
Sampo OYJ
PINK:SAXPY
 		$28.18 Billion
Veeva Systems Inc.
LSE:0LO3
 		$28.17 Billion
Veeva Systems Inc Class A
NYSE:VEEV
 		$28.17 Billion
Amadeus IT Group S.A
PINK:AMADF
 		$28.16 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Hengrui Medicine Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 40,465,795,358 to 45,519,861,860, a change of 5,054,066,502 (12.5%).
  • Net income of 6,336,527,014 contributed positively to equity growth.
  • Dividend payments of 1,274,788,274 reduced retained earnings.
  • Share repurchases of 228,426,456 reduced equity.
  • Other comprehensive income decreased equity by 2,352,162.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥6.34 Billion +13.92%
Dividends Paid CN¥1.27 Billion -2.8%
Share Repurchases CN¥228.43 Million -0.5%
Other Comprehensive Income CN¥-2.35 Million -0.01%
Other Changes CN¥223.11 Million +0.49%
Total Change CN¥- 12.49%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Hengrui Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 7.67x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 1953.26x to 7.67x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-12-31 CN¥0.03 CN¥55.11 x
1998-12-31 CN¥0.04 CN¥55.11 x
1999-12-31 CN¥0.05 CN¥55.11 x
2000-12-31 CN¥0.20 CN¥55.11 x
2001-12-31 CN¥0.22 CN¥55.11 x
2002-12-31 CN¥0.24 CN¥55.11 x
2003-12-31 CN¥0.27 CN¥55.11 x
2004-12-31 CN¥0.29 CN¥55.11 x
2005-12-31 CN¥0.33 CN¥55.11 x
2006-12-31 CN¥0.20 CN¥55.11 x
2007-12-31 CN¥0.26 CN¥55.11 x
2008-12-31 CN¥0.32 CN¥55.11 x
2009-12-31 CN¥0.42 CN¥55.11 x
2010-12-31 CN¥0.54 CN¥55.11 x
2011-12-31 CN¥0.67 CN¥55.11 x
2012-12-31 CN¥0.83 CN¥55.11 x
2013-12-31 CN¥1.01 CN¥55.11 x
2014-12-31 CN¥1.26 CN¥55.11 x
2015-12-31 CN¥1.57 CN¥55.11 x
2016-12-31 CN¥1.96 CN¥55.11 x
2017-12-31 CN¥2.41 CN¥55.11 x
2018-12-31 CN¥3.07 CN¥55.11 x
2019-12-31 CN¥3.91 CN¥55.11 x
2020-12-31 CN¥4.80 CN¥55.11 x
2021-12-31 CN¥5.49 CN¥55.11 x
2022-12-31 CN¥5.94 CN¥55.11 x
2023-12-31 CN¥6.40 CN¥55.11 x
2024-12-31 CN¥7.18 CN¥55.11 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Hengrui Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 13.92%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 22.64%
  • • Asset Turnover: 0.56x
  • • Equity Multiplier: 1.10x
  • Recent ROE (13.92%) is below the historical average (19.28%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 43.58% 13.53% 1.05x 3.07x CN¥31.65 Million
1998 30.94% 11.88% 1.00x 2.62x CN¥29.26 Million
1999 32.00% 12.40% 0.89x 2.89x CN¥35.29 Million
2000 9.74% 13.47% 0.49x 1.47x CN¥-1.77 Million
2001 10.92% 12.80% 0.57x 1.51x CN¥6.85 Million
2002 9.97% 10.44% 0.63x 1.52x CN¥-256.01K
2003 10.66% 9.00% 0.72x 1.64x CN¥5.85 Million
2004 12.46% 10.71% 0.91x 1.28x CN¥24.24 Million
2005 14.82% 13.76% 0.92x 1.17x CN¥52.72 Million
2006 16.59% 14.53% 0.98x 1.17x CN¥82.10 Million
2007 25.56% 21.07% 0.97x 1.25x CN¥251.35 Million
2008 21.21% 17.68% 1.06x 1.13x CN¥223.51 Million
2009 25.53% 21.98% 1.01x 1.15x CN¥404.96 Million
2010 21.38% 19.34% 0.96x 1.15x CN¥385.44 Million
2011 20.75% 19.26% 0.94x 1.14x CN¥454.19 Million
2012 20.66% 19.82% 0.92x 1.13x CN¥555.97 Million
2013 19.48% 19.96% 0.86x 1.14x CN¥602.39 Million
2014 19.10% 20.34% 0.82x 1.15x CN¥722.13 Million
2015 21.87% 23.31% 0.81x 1.16x CN¥1.18 Billion
2016 20.90% 23.34% 0.77x 1.16x CN¥1.35 Billion
2017 20.93% 23.25% 0.77x 1.17x CN¥1.68 Billion
2018 20.61% 23.34% 0.78x 1.13x CN¥2.09 Billion
2019 21.51% 22.88% 0.85x 1.11x CN¥2.85 Billion
2020 20.75% 22.82% 0.80x 1.14x CN¥3.28 Billion
2021 12.94% 17.49% 0.66x 1.12x CN¥1.03 Billion
2022 10.33% 18.36% 0.50x 1.12x CN¥123.99 Million
2023 10.63% 18.85% 0.52x 1.08x CN¥255.86 Million
2024 13.92% 22.64% 0.56x 1.10x CN¥1.78 Billion

Industry Comparison

This section compares Jiangsu Hengrui Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangsu Hengrui Medicine Co Ltd (600276) CN¥60.03 Billion 43.58% 0.14x $28.19 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million